Skip to main content

Advertisement

Table 2 Risk factors of everolimus-associated AKI in the RCC group: Cox proportional hazard models

From: Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function

Variable Univariate analysis Multivariate analysis*
HR (95% CI) P-value HR (95% CI) P-value
Age (per 10 years) 1.83 (1.05–3.21) 0.034 1.54 (0.84–2.81) 0.162
Male (vs female) 0.85 (0.19–3.82) 0.836   
DM 0.70 (0.16–3.14) 0.643   
HTN 0.74 (0.23–2.36) 0.609   
eGFR (per 10 mL/min/1.73 m2) 0.74 (0.57–0.96) 0.022 0.70 (0.49–1.00) 0.047
Radical nephrectomy 0.64 (0.20–2.06) 0.456   
Proteinuria 2.23 (0.75–6.63) 0.150   
ACE inhibitor/ARB 1.21 (0.34–4.34) 0.769   
Diuretics 1.09 (0.38–3.13) 0.880   
  1. AKI, acute kidney injury; RCC, renal cell carcinoma; HR, hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; ACE inhibitor, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
  2. *This model includes age, sex, and eGFR.